Pacira BioSciences Inc (PCRX)

Industry Drug Manufacturers - Specialty & Generic
This stock can be held in an Investment ISA and an Investment Account
Sell

$20.02

Buy

$29.19

arrow-down$-0.09 (-0.35%)

Prices updated at 30 May 2025, 22:04 EDT
| Prices minimum 15 mins delay
|
Prices in USD
Pacira Pharmaceuticals Inc is a specialty and generic drug manufacturing company. The company develops, manufactures, and commercializes pharmaceutical products for use in hospitals and ambulatory surgery centers across the United States.
NASDAQ
arrow-down-0.32%
NASDAQ
Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and
Our Investment Fees and Charges.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Chairman
Ms. Laura A. Brege
CEO
Mr. Frank D. Lee
Most recent earnings
31 Dec 2024
Fiscal year end
31 Dec 2024
Employees
790
Head office
5401 West Kennedy Boulevard
Tampa
United States
33609
mobile
+1 813 553-6680
letter
Susan.Mesco@pacira.com
computer
Company website

Key personnel

Owner name
chevron-l-regular
chevron-r-regular
Salary
Ms. Laura A. Brege
Chairman of the Board
0.09m
Mr. Brendan P. Teehan
Chief Commercial Officer
-
Mr. Daryl Gaugler
Executive Vice President, Commercial Operations
0.51m
Ms. Krys Corbett
Chief Business Officer
-
Dr. Mark A. Kronenfeld, M.D.
Independent Director
0.09m
Ms. Kristen Marie Williams
Chief Administrative Officer and Secretary
0.52m
Mr. Michael J. Yang
Independent Director
0.07m
Dr. Mark I. Froimson, M.D.
Independent Director
0.07m
Mr. Abraham N. Ceesay, M.B.A.
Independent Director
0.06m
Governor Christopher J. Christie
Independent Director
0.05m
Mr. Shawn M. Cross
Chief Financial Officer
0.10m
Mr. Frank D. Lee
Director and Chief Executive Officer
0.90m
Mr. Jonathan Slonin
Chief Medical Officer
0.54m
Ms. Alethia Young
Independent Director
0.07m
Dr. Marcelo Bigal, M.D.,PhD
Independent Director
0.07m

Top 5 shareholders

Owner name
chevron-l-regular
chevron-r-regular
No. of shares
BlackRock Inc7,653,363
Vanguard Group Inc5,241,804
BlackRock Fund Advisors5,057,134
Pacer Advisors, INC.3,262,837
iShares Core S&P Small-Cap ETF2,803,671

Director dealings

Date
chevron-l-regular
chevron-r-regular
Action
31 Dec 2024-
13 Dec 2024-
04 Nov 2024-
01 Nov 2024-
13 Sep 2024-
16 Aug 2024-
16 Aug 2024-
14 Aug 2024-
12 Aug 2024-
12 Aug 2024-
12 Aug 2024-
02 Aug 2024-
01 Aug 2024-
01 Jul 2024-
28 Jun 2024-
02 Jul 2024-
28 Jun 2024-
12 Jun 2024-
12 Jun 2024-
13 Jun 2024-
Please note that past performance is not a reliable indicator of future returns.


Important Information

Please note the value of investments can go down as well as up so you may get back less than you invested. This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to an authorised financial adviser. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and(3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.
© Copyright 2025 Morningstar. All rights reserved.